Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

From Skin Biopsy to Neurons Through a Pluripotent Intermediate Under Good Manufacturing Practice Protocols

7 Dec 2011

Abstract excerpt

The clinical application of human-induced pluripotent stem cells (hiPSCs) requires not only the production of Good Manufacturing Practice-grade (GMP-grade) hiPSCs but also the derivation of specified cell types for transplantation under GMP conditions. Previous reports have suggested that hiPSCs can be produced in the absence of animal-derived reagents (xenobiotics) to ease the transition to production under GMP...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomedical Ethics and Regulation
Share to CRISPR and Genetic Engineering
Share to Pluripotent Stem Cells Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23197638
DOI: 10.5966/sctm.2011-0001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

From Skin Biopsy to Neurons Through a Pluripotent Intermediate Under Good Manufacturing Practice ProtocolsPMID 23197638Read ↗

Good Manufacturing Practice–compliant human induced pluripotent stem cells: from bench to putative clinical productsSemantic proximity Read ↗

Minimizing time in culture: A prototypic autologous manufacturing workflow for monoclonal iPSC lines within seven weeksSemantic proximity Read ↗

Generation and characterization of transgene-free human induced pluripotent stem cells and conversion to putative clinical-grade statusSemantic proximity Read ↗

Rapid and Efficient Conversion of Integration-Free Human Induced Pluripotent Stem Cells to GMP-Grade Culture ConditionsSemantic proximity Read ↗

Important precautions when deriving patient-specific neural elements from pluripotent cellsSemantic proximity Read ↗

Neural Differentiation of Human Pluripotent Stem Cells for Nontherapeutic Applications: Toxicology, Pharmacology, andIn VitroDisease ModelingSemantic proximity Read ↗

Human-Induced Pluripotent Stem Cells Manufactured Using a Current Good Manufacturing Practice-Compliant Process Differentiate Into Clinically Relevant Cells From Three Germ LayersSemantic proximity Read ↗

GMP-compatible manufacturing of three iPS cell lines from human peripheral bloodSemantic proximity Read ↗

Harmonizing standards for producing clinical-grade therapies from pluripotent stem cellsSemantic proximity Read ↗

A scalable and cGMP-compatible autologous organotypic cell therapy for Dystrophic Epidermolysis Bullosa.Semantic proximity Read ↗

Long-term culture of skin biopsies: Maintenance of fibroblast production and competency of reprogrammingSemantic proximity Read ↗

A practical guide to induced pluripotent stem cell research using patient samplesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.